mitoxantrone has been researched along with Pain in 22 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)." | 9.12 | Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 9.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "Treatment with cabazitaxel was prognostic for survival ≥2 years." | 6.78 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. ( Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013) |
| "To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
| "Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)." | 5.12 | Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 5.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "One hundred nine patients with nonmetastatic breast carcinoma, recruited between May 1995 and February 1997, were included in a protocol combining chemotherapy with mitoxantrone and cyclophosphamide, administered intravenously in 4 cycles of 21 days, and concomitant radiotherapy." | 5.09 | Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life, and organization. ( Bouscary, ML; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Moatti, JP; Resbeut, M; Viens, P, 1999) |
| "We randomized 161 hormone-refractory patients with pain to receive mitoxantrone plus prednisone or prednisone alone (10 mg daily)." | 5.08 | Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. ( Armitage, GR; Coppin, CM; Ernst, DS; Moore, MJ; Murphy, KC; Neville, AJ; Osoba, D; Stockler, MR; Tannock, IF; Venner, PM; Wilson, JJ, 1996) |
| " As a result, mitoxantrone plus prednisone has been demonstrated to be a useful palliative therapy that provides improvements in pain and quality of life for approximately 40% of those treated." | 4.81 | Treatment of hormone refractory prostate cancer. ( Knox, JJ; Moore, MJ, 2001) |
| " The evaluated palliative treatments were pain medication only, chemotherapy consisting of mitoxantrone and prednisone, and single- and multifraction radiotherapy (RT)." | 3.72 | Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. ( Konski, A, 2004) |
| "Treatment with cabazitaxel was prognostic for survival ≥2 years." | 2.78 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. ( Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013) |
| "The average treatment levels of pain did not differ, hence, the average mediated effect of treatment on GHRQL was zero." | 2.74 | Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. ( Donaldson, GW; Moinpour, CM; Nakamura, Y, 2009) |
| " Neutropenia is the most common toxicity associated with mitoxantone therapy and may necessitate dosage reduction in some patients." | 2.40 | Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. ( Spencer, CM; Wiseman, LR, 1997) |
| "In early-stage cervical cancer may not show any symptoms, however, as the cancer progresses, some people may experience- abnormal vaginal bleeding, watery or bloody vaginal discharge, pain in the pelvis or lower back, pain during sex, and frequent and painful urination." | 1.91 | Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MM\\GBSA and MD simulation study. ( Alam, Q; Alazragi, RS; Alnamshan, MM; Alqahtani, LS; Alqosaibi, AI; Alshehri, MA; Alzahrani, A; Asiri, SA; Rafeeq, MM, 2023) |
| "Mitoxantrone has not been compared with palliative care comprising radiotherapy." | 1.31 | Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer. ( , 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Alshehri, MA | 1 |
| Asiri, SA | 1 |
| Alzahrani, A | 1 |
| Alazragi, RS | 1 |
| Alqahtani, LS | 1 |
| Alqosaibi, AI | 1 |
| Alnamshan, MM | 1 |
| Alam, Q | 1 |
| Rafeeq, MM | 1 |
| Bahl, A | 1 |
| Oudard, S | 3 |
| Tombal, B | 1 |
| Ozgüroglu, M | 1 |
| Hansen, S | 1 |
| Kocak, I | 1 |
| Gravis, G | 2 |
| Devin, J | 1 |
| Shen, L | 2 |
| de Bono, JS | 1 |
| Sartor, AO | 1 |
| Halabi, S | 2 |
| Lin, CY | 1 |
| Small, EJ | 1 |
| Armstrong, AJ | 2 |
| Kaplan, EB | 1 |
| Petrylak, D | 1 |
| Sternberg, CN | 1 |
| de Bono, J | 1 |
| Sartor, O | 1 |
| Taneja, SS | 1 |
| Saad, F | 1 |
| Ruether, D | 1 |
| Ernst, S | 1 |
| North, S | 1 |
| Cheng, T | 1 |
| Perrotte, P | 1 |
| Karakiewicz, P | 1 |
| Winquist, E | 1 |
| Moinpour, CM | 2 |
| Donaldson, GW | 1 |
| Nakamura, Y | 1 |
| Banu, E | 1 |
| Medioni, J | 1 |
| Scotte, F | 1 |
| Banu, A | 1 |
| Levy, E | 1 |
| Wasserman, J | 1 |
| Kacso, G | 1 |
| Andrieu, JM | 1 |
| Ernst, DS | 2 |
| Tannock, IF | 2 |
| Winquist, EW | 1 |
| Venner, PM | 2 |
| Reyno, L | 1 |
| Moore, MJ | 3 |
| Chi, K | 1 |
| Ding, K | 1 |
| Elliott, C | 1 |
| Parulekar, W | 1 |
| Rexer, H | 1 |
| Konski, A | 1 |
| Berry, DL | 1 |
| Jiang, CS | 1 |
| Ankerst, DP | 1 |
| Petrylak, DP | 1 |
| Vinson, LV | 1 |
| Lara, PN | 1 |
| Jones, S | 1 |
| Taplin, ME | 1 |
| Burch, PA | 1 |
| Hussain, MH | 1 |
| Crawford, ED | 1 |
| Valencak, J | 1 |
| Troch, M | 1 |
| Raderer, M | 1 |
| Garrett-Mayer, E | 1 |
| Ou Yang, YC | 1 |
| Carducci, MA | 1 |
| Tannock, I | 1 |
| de Wit, R | 2 |
| Eisenberger, M | 2 |
| Berthold, DR | 1 |
| Pond, GR | 1 |
| Roessner, M | 1 |
| Tannock, AI | 1 |
| Dreosti, LM | 1 |
| Bezwoda, W | 1 |
| Gunter, K | 1 |
| Bjermer, L | 1 |
| Gruber, A | 1 |
| Sue-Chu, M | 1 |
| Sandström, T | 1 |
| Eksborg, S | 1 |
| Henriksson, R | 1 |
| Osoba, D | 1 |
| Stockler, MR | 1 |
| Neville, AJ | 1 |
| Armitage, GR | 1 |
| Wilson, JJ | 1 |
| Coppin, CM | 1 |
| Murphy, KC | 1 |
| Wiseman, LR | 1 |
| Spencer, CM | 1 |
| Macquart-Moulin, G | 1 |
| Viens, P | 1 |
| Genre, D | 1 |
| Bouscary, ML | 1 |
| Resbeut, M | 1 |
| Camerlo, J | 1 |
| Maraninchi, D | 1 |
| Moatti, JP | 1 |
| Kantoff, PW | 1 |
| Conaway, M | 1 |
| Picus, J | 1 |
| Kirshner, J | 1 |
| Hars, V | 1 |
| Trump, D | 1 |
| Winer, EP | 1 |
| Vogelzang, NJ | 1 |
| Knox, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079] | Phase 3 | 755 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286] | Phase 2 | 140 participants (Anticipated) | Interventional | 2017-11-30 | Not yet recruiting | ||
| Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.[NCT00973882] | Phase 2 | 60 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336] | Phase 2 | 1 participants (Actual) | Interventional | 2017-01-06 | Terminated (stopped due to can not meet enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 12.7 |
| Cabazitaxel + Prednisone | 15.1 |
"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 4.4 |
| Cabazitaxel + Prednisone | 14.4 |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 7.7 |
| Cabazitaxel + Prednisone | 9.2 |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 17.8 |
| Cabazitaxel + Prednisone | 39.2 |
"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | NA |
| Cabazitaxel + Prednisone | 11.1 |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 1.4 |
| Cabazitaxel + Prednisone | 2.8 |
"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 3.1 |
| Cabazitaxel + Prednisone | 6.4 |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 5.4 |
| Cabazitaxel + Prednisone | 8.8 |
Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Calcitriol, Ketoconazole, Hydrocortisone | 1 |
2 reviews available for mitoxantrone and Pain
| Article | Year |
|---|---|
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
Topics: Antineoplastic Agents; Cardiovascular System; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; | 1997 |
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Est | 2001 |
13 trials available for mitoxantrone and Pain
| Article | Year |
|---|---|
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mi | 2013 |
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomar | 2013 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; | 2009 |
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Humans; M | 2009 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progre | 2003 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone; | 2008 |
Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion--a randomised study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fever; Humans; Male; Middle Aged; Mit | 1995 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life, and organization.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast | 1999 |
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydrocorti | 1999 |
7 other studies available for mitoxantrone and Pain
| Article | Year |
|---|---|
Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MM\\GBSA and MD simulation study.
Topics: Cell Cycle Proteins; Female; Humans; Mitoxantrone; Molecular Docking Simulation; Molecular Dynamics | 2023 |
Re: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Humans; Male; Mitoxantrone; Pain; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; | 2004 |
Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Cost-Benefit Analysis; Humans; Male; Markov Chain | 2004 |
Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Edem | 2007 |
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.
Topics: Bone Marrow; Female; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; L | 1994 |
Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; France; Humans; Male; Mi | 2001 |